A scientific study published in the journal Nature - "Ketamine and rapid antidepressant action: new treatments and novel synaptic signaling mechanisms" - focused on neuropsychopharmacology - a branch of science that studies the effects of drugs on the nervous system and behavior, especially in the treatment of psychiatric and neurological disorders - explores how psychedelics act on the brain and their antidepressant effects.
New Era in the Treatment of Depression: Revolutionary Discoveries on Antidepressant Mechanisms
Psychiatric medicine is undergoing a transformation with the arrival of innovative new treatments for depression. After decades of reliance on traditional antidepressants, such as serotonin reuptake inhibitors, completely different approaches are now emerging - and much faster, according to the scientific studies that have been carried out in recent years.
The approval of esketamine (Spravato) and brexanolone (Zulresso) in 2019 paved the way for substances such as psilocybin and MDMA, which could be the next to receive regulatory approval.
The big change? Instead of acting on "slow" neurotransmitters such as serotonin and noradrenaline, the new treatments focus on glutamate - one of the main neurotransmitters in the central nervous system, responsible for rapid communication between neurons and with fundamental functions such as learning, memory, synaptic plasticity and even mood regulation.
For decades, the antidepressants available were based on the monoaminergic model, focusing on neurotransmitters (such as serotonin and noradrenaline). However, the limited effectiveness of these therapies has highlighted the need for new approaches. The latest study indicates that ketamine, an NMDA receptor antagonist, has brought a significant advance in understanding the neurobiological mechanisms of depression.
Ketamine, an anesthetic that began to be studied for resistant depression, has shown surprising effects, providing almost immediate relief from depressive symptoms, even in people who do not respond to conventional treatments.
The researchers found that ketamine triggers a cascade of reactions in the brain, stimulating the growth of new neuronal connections and activating mechanisms essential for emotional balance.
In addition, there is evidence that its metabolites and even the immune system itself play a crucial role in its antidepressant effects.
Ketamine metabolites and their role in depression
Metabolites are substances that result from the metabolism of a substance in our body. When a drug such as ketamine is administered, it undergoes chemical transformation processes in our body, such as in the liver and other organs, giving rise to metabolites which can have their own effects on the body.
In the case of ketamine, some of its metabolites have demonstrated independent antidepressant activity, which means that their effect may not be limited to the action of the original substance. An important example is HNK (hydroxynorketamine), a metabolite that seems to contribute to the therapeutic effects of ketamine without causing dissociation - one of the side effects of the original drug.
These findings have opened up new lines of research for the development of safer and more effective treatments, exploiting the action of metabolites to obtain the antidepressant benefits of ketamine without its adverse effects.
Research continues to evolve, focused on developing more effective therapies with fewer side effects and faster action. The key to revolutionizing mental health and its treatment lies in the way our brain communicates.
Read the full article here.
